Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARLET: Citicoline for COVID-19 Respiratory Failure
NCT05881135Phase 2Active, not recruiting
- Sponsor
- The Ohio State University
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of citicoline in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by The Ohio State University. Primary endpoints: Safety of citicoline up to 29 days and SpO2/FiO2 ratio at Day 3. Started Jun 2023; status: active, not recruiting.
02
Drugs
citicoline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05881135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05881135.